A dispute between the American Red Cross and the U.S. Justice Department has heated up over the interpretation of U.S. antitrust law. The Justice Department has backed a key legal claim from a biomedical company, Verax Biomedical, against the Red Cross. Lawyers for the Red Cross argued that the nonprofit organization is not subject to the Sherman Act federal antitrust law, but the Justice Department refused and asserted that the Red Cross is separate from the federal government and is liable to the law.
In their lawsuit, Verax Biomedical alleges that the Red Cross is using their market dominance in the field of blood platelets to suppress competition for anti-contamination services. The Red Cross referred to the government’s argument as “novel” and warned that it could lead to other organizations that fulfill ‘vital government functions’ to become liable to federal antitrust law. In opposition, the Justice Department stated the Red Cross “made a misreading of the law”. Verax Biomedical fully supported the Justice Department’s assertions, referring to their statement and arguments as “comprehensive and persuasive”.
Read more: American Red Cross Hit With New Antitrust Suit
Although the Justice Department did not argue that the Red Cross should be found liable for antitrust violations, their argument indicates a possible change in the legal stance towards nonprofit organizations and monopolies. It remains to be seen how this case will unfold, and how other entities may be affected by it. The case is Verax Biomedical Inc v. American National Red Cross, U.S. District Court for the District of Massachusetts, No. 1:23-cv-10335-PBS.
Source: Reuters
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI